These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6428775)

  • 1. Progress in coronary artery disease risk-factor research: what remains to be done?
    Crouse JR
    Clin Chem; 1984 Jul; 30(7):1125-7. PubMed ID: 6428775
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasma apolipoprotein B and VLDL-, LDL-, and HDL-cholesterol as risk factors in the development of coronary artery disease in male patients examined by angiography.
    Whayne TF; Alaupovic P; Curry MD; Lee ET; Anderson PS; Schechter E
    Atherosclerosis; 1981 Jun; 39(3):411-24. PubMed ID: 6942843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HDL-cholesterol, apo-A-I and apo-E levels in patients with abnormal coronary arteries.
    Tan MH; Weldon KL; Albers JJ; Cheung MC; Havel RJ; Vigne JL
    Clin Invest Med; 1980; 3(3-4):225-32. PubMed ID: 6784991
    [No Abstract]   [Full Text] [Related]  

  • 4. [Value of the analysis of lipoproteins after myocardial infarction].
    Dewailly P; Mellin D; Moulin S; Rouget JP; Sezille G; Jaillard J
    Presse Med; 1983 Jul 9-16; 12(29):1807-10. PubMed ID: 6224195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease.
    Kannel WB
    Am J Cardiol; 1983 Aug; 52(4):9B-12B. PubMed ID: 6577783
    [No Abstract]   [Full Text] [Related]  

  • 6. Plasma lipids and apolipoproteins as discriminators for presence and severity of angiographically defined coronary artery disease.
    Noma A; Yokosuka T; Kitamura K
    Atherosclerosis; 1983 Oct; 49(1):1-7. PubMed ID: 6651909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estradiol, testosterone, apolipoproteins, lipoprotein cholesterol, and lipolytic enzymes in men with premature myocardial infarction and angiographically assessed coronary occlusion.
    Mendoza SG; Zerpa A; Carrasco H; Colmenares O; Rangel A; Gartside PS; Kashyap ML
    Artery; 1983; 12(1):1-23. PubMed ID: 6431945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Various lipoprotein fractions and their relation to ischemic heart disease].
    Palazzuoli V; Mondillo S; Kristodhullu A; De Stefano R; Amatucci G
    G Ital Cardiol; 1983; 13(2):90-4. PubMed ID: 6884650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoproteins, apolipoproteins and coronary artery disease.
    Fruchart JC; Parra H; Cachera C; Clavey V; Bertrand M
    Ric Clin Lab; 1982; 12(1):101-6. PubMed ID: 6806881
    [No Abstract]   [Full Text] [Related]  

  • 10. [Quantitative determination of apolipoprotein A in human serum by laser nephelometry].
    Girault A; Loiseau D; Girault M
    Ric Clin Lab; 1981; 11 Suppl 2():19-29. PubMed ID: 6798675
    [No Abstract]   [Full Text] [Related]  

  • 11. The association of serum lipids, lipoproteins, and apolipoproteins with coronary artery disease assessed by coronary arteriography.
    Naito HK
    Ann N Y Acad Sci; 1985; 454():230-8. PubMed ID: 3865610
    [No Abstract]   [Full Text] [Related]  

  • 12. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease.
    Maciejko JJ; Holmes DR; Kottke BA; Zinsmeister AR; Dinh DM; Mao SJ
    N Engl J Med; 1983 Aug; 309(7):385-9. PubMed ID: 6410239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol acyltransferase activity in diabetes mellitus.
    Schernthaner G; Kostner GM; Dieplinger H; Prager R; Mühlhauser I
    Atherosclerosis; 1983 Dec; 49(3):277-93. PubMed ID: 6229255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid metabolism disorders in patients with retinal artery occlusions].
    Fellinger C; Schmut O; Hofmann H
    Klin Monbl Augenheilkd; 1984 Feb; 184(2):109-11. PubMed ID: 6716886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of procetofen on apolipoprotein A I and B concentrations in hyperlipoproteinemia.
    Viikari J; Solakivi-Jaakkola T; Lehtonen A
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):362-5. PubMed ID: 6811447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma lipoproteins and coronary heart disease.
    Scanu AM
    Ann Clin Lab Sci; 1978; 8(2):79-83. PubMed ID: 205164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of elective hospitalization on plasma lipoprotein cholesterol and apolipoproteins A-I, B and Lp(a).
    Genest JJ; McNamara JR; Ordovas JM; Martin-Munley S; Jenner JL; Millar J; Salem DN; Schaefer EJ
    Am J Cardiol; 1990 Mar; 65(9):677-9. PubMed ID: 2106773
    [No Abstract]   [Full Text] [Related]  

  • 18. LDL molecular size as risk factor in coronary artery disease.
    Kozma L; Fodor J; Chockalingam A; Sussex B
    Acta Med Hung; 1992-1993; 49(1-2):65-77. PubMed ID: 1296188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocholesterolemia in myeloproliferative diseases with myelofibrosis.
    Ginsberg H; Gilbert HS
    Prog Clin Biol Res; 1984; 154():345-57. PubMed ID: 6382303
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduced LDL- and increased HDL-apoproteins in patients with hypercholesterolaemia under treatment with bezafibrate.
    Mordasini R; Riesen W; Oster P; Keller M; Middelhoff G; Lang PD
    Atherosclerosis; 1981 Oct; 40(2):153-8. PubMed ID: 6796096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.